Table 2.

Patient characteristics by SARS-CoV-2 antibody status

VariableAntibody Positive (%), n=129Antibody Negative (%), n=227P Value
Sex
 Women47 (36.4)83 (36.6)0.98
 Men82 (63.6)144 (63.4)
Age (median), yr65 (55–73)68 (57–77)0.05a
Ethnicity
 Black18 (14.0)28 (12.3)0.36
 White29 (22.5)61 (26.9)
 Indoasian60 (46.5)94 (41.4)
 Other22 (17.1)44 (19.4)
Cause of ESKD
 APKD6 (4.7)13 (5.7)0.90
 Diabetic nephropathy48 (37.2)86 (37.9)
 GN19 (14.7)42 (18.5)
 Other12 (9.3)37 (16.3)
 Unknown38 (29.5)42 (18.5)
 Urologic6 (4.7)7 (3.1)
Time at ESKD (median), yr1.7 (0.9–3.2)2.2 (0.9–4.0)0.18
Unit
 A51 (39.5)47 (20.7)<0.001a
 B78 (60.5)180 (79.3)
Lymphocyte nadir (median), 109/L1.1 (0.7–1.4)1.2 (0.9–1.5)0.01a
CRP peak (median), mg/L32.7 (7.1–87.9)9.8 (3.6–24.5)<0.001a
Ferritin peak (median), μg/L610 (426–1044)417 (299–545)<0.001a
Immunosuppressed, yes14 (10.9)41 (18.0)0.07
  • APKD, autosomal dominant polycystic kidney disease.

  • a P<0.05.